A review of current evidence for vilazodone in major depressive disorder

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue 3, 2013, Pages 160-169

  Wang, Sheng Min ^a   Han, Changsu ^b   Lee, Soo Jung ^a   Patkar, Ashwin A ^c   Masand, Prakash S ^d   Pae, Chi Un ^a,c  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Global Medical Education Inc   (United States)

Author keywords

Action mechanism; Antidepressant; Major depressive disorder; Vilazodone

Indexed keywords

CAFFEINE; CIMETIDINE; DEBRISOQUINE; FLURBIPROFEN; NIFEDIPINE; PANTOPRAZOLE; PLACEBO; SEROTONIN; VILAZODONE; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR;

ANORGASMIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; DIARRHEA; DIZZINESS; DREAM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; ERECTILE DYSFUNCTION; FACILITATION; FATIGUE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; IC 50; IN VITRO STUDY; INSOMNIA; LIBIDO; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROTRANSMISSION; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; RHINOPHARYNGITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VOMITING; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; EVIDENCE BASED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

BENZOFURANS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSIVE DISORDER, MAJOR; EVIDENCE-BASED MEDICINE; HUMANS; INDOLES; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN; TREATMENT OUTCOME;

EID: 84883186520     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2013.794245     Document Type: Article

References (59)

1. Administration. 2012. UFaD. Vilazodone Drug Approval Package. ed eds.
2. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. 2008. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22: 343-396.
3. Artigas F, Perez V, Alvarez E. 1994. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248-251.
4. Barowsky J, Schwartz TL. 2006. An evidence-based approach to augmentation and combination strategies for: treatment-resistant depression. Psychiatry (Edgmont) 3: 42-61.
5. Bartoszyk GD, Hegenbart R, Ziegler H. 1997. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 322 : 147-153.
6. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. 2009. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70: 540-549.
7. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. 2000. Meta-analysis of randomised controlled trials of fl uoxetine v. placebo and tricyclic antidepressants in the shortterm treatment of major depression. Br J Psychiatry 176: 421-428.
8. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. 2007. Th e effi cacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843-853.
9. Blier P, Abbott FV. 2001. Putative mechanisms of action of antidepressant drugs in aff ective and anxiety disorders and pain. J Psychiatry Neurosci 26: 37-43.
10. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R. 2010. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167: 281-288.
11. Bouwer C, Stein DJ. 1997. Buspirone is an eff ective augmenting agent of serotonin selective re-uptake inhibitors in severe treatmentrefractory depression. S Afr Med J 87: 534-537, 540.
12. Briley M, Moret C. 1993. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16: 387-400.
13. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. 2004. Th e therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29: 252-265.
14. Citrome L. 2012. Vilazodone for major depressive disorder: a systematic review of the effi cacy and safety profi le for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 66: 356-368.
15. Clayton AH, Montejo AL. 2006. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 67 : 33-37.
16. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. 2002. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry; 63: 357-366.
17. Dawson LA, Watson JM. 2009. Vilazodone: a 5-HT1A receptor agonist/ serotonin transporter inhibitor for the treatment of aff ective disorders. CNS Neurosci Th er 15: 107-117.
18. Driver HS, Flanigan MJ, Bentley AJ, Luus HG, Shapiro CM, Mitchell D. 1995. Th e infl uence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects. Psychopharmacology (Berl ) 117 : 186-192.
19. Duxon MS, Starr KR, Upton N. 2000. Latency to paroxetine-induced anxiolysis in therat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635. Br J Pharmacol 130: 1713-1719.
20. Egede LE. 2007. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 29: 409-416.
21. Ferguson JM. 2001. SSRI antidepressant medications: adverse eff ects and tolerability. Prim Care Companion J Clin Psychiatry 3 : 22-27.
22. Forest Pharmaceuticals I. 2012. Viibryd (Vilazodone) Prescribing Information, edêds.
23. Gartlehner G, Hansen RA, Morgan LC, Th aler K, Lux L, Van Noord M, et al. 2011. Comparative benefi ts and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 155: 772-785.
24. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. 2000. Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 14: 177-185.
25. Hogg S, Dalvi A. 2004. Acceleration of onset of action in scheduleinduced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacol Biochem Behav 77: 69-75.
26. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, et al. 2005. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510: 49-57.
27. Hughes ZA, Starr KR, Scott CM, Newson MJ, Sharp T, Watson JM, et al. 2007. Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology (Berl) 192: 121-133.
28. Jo SJ, Yim HW, Bang MH, Lee MO, Jun TY, Choi JS, et al. 2011. Th e Association between Economic Status and Depressive Symptoms: An Individual and Community Level Approach. Psychiatry Investig 8 : 194-200.
29. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, et al. 2011. A randomized, double-blind, placebocontrolled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 72: 441-447.
30. Khan A. 2009. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 18 : 1753-1764.
31. Kocsis JH, Leon AC, Markowitz JC, Manber R, Arnow B, Klein DN, Th ase ME. 2009. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 70: 354-361.
32. Lanfumey L, Hamon M. 2000. Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl Med Biol 27: 429-435.
33. Le Poul E, Laaris N, Doucet E, Laporte AM, Hamon M, Lanfumey L. 1995. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fl uoxetine or paroxetine. Naunyn Schmiedebergs Arch Pharmacol 352: 141-148.
34. Li Q, Muma NA, Battaglia G, Van de Kar LD. 1997. Adesensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of G(i) and G(o) proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. J Pharmacol Exp Ther; 282: 1581-1590.
35. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. 2008. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28: 156-165.
36. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E. 2010. Th e neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 15: 237-249.
37. Morganroth J, Th orn MD, Gallipoli S, Sperry V, Longstreth J, Adams MH, Reed CR. 2010. An evaluation of the eff ect of vilazodone on cardiac safety. 45th Am Soc Health System Pharmacists Midyear Clin Meet & Exhib (Dec 5-9, Anaheim), Poster 3-176.
38. Murck H, Frieboes RM, Antonijevic IA, Steiger A. 2001. Distinct temporal pattern of the eff ects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology (Berl) 155 : 187-192.
39. Nelson JC, Papakostas GI. 2009. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166: 980-991.
40. Newman-Tancredi A. 2010. Th e importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11: 802-812.
41. Nierenberg AA. 2009. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother Psychosom 78: 391-393.
42. Othmer E, Othmer SC. 1987. Eff ect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 48 : 201-203.
43. Quattrochi JJ, Mamelak AN, Binder D, Williams J, Hobson JA. 1993. Dose-related suppression of REM sleep and PGO waves by the serotonin-1 agonist eltoprazine. Neuropsychopharmacology 8: 7-13.
44. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. 2009. Evidence for effi cacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double- blind, placebo-controlled trial. J Clin Psychiatry 70: 326-333.
45. Roberts C, Hagan JJ, Bartoszyk GD, Kew JN. 2005. Eff ect of vilazodone on 5-HT effl ux and re-uptake in the guinea-pig dorsal raphe nucleus. Eur J Pharmacol; 517: 59-63.
46. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. 2011. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 31: 643-646.
47. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR, Dreport. Am J Psychiatry 163: 1905-1917.
48. Rush AJ. 2007. STAR, D: what have we learned? Am J Psychiatry 164 : 201-204.
49. Schatzberg AF, Cole JO, DeBattista C. 2010. Manual of Clinical Psychopharmacology, 7th ed. Washington, DC: American Psychiatric Publishing, Inc. Seifritz E, Stahl SM, Gillin JC. 1997. Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity. Brain Res 759 : 84-91.
50. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. 1996. Th e eff ects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 126: 50-54.
51. Sorbera LA, Rabassada X, Silvestre J, Castaner J. 2001. Vilazodone hydrochloride-Antidepressant-5-HT1A partial agonist-5-HT reuptake inhibitor. Drugs Future 26 : 247-252.
52. Stahl S. 2011. Essential Psychopharmacology: Th e Prescriber ' s Guide. Cambridge, UK: Cambridge University Press.
53. Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, et al. 2007. SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacology 32: 2163-2172.
54. Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G. 2012. Cost-eff ectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Ann Pharmacother 46 : 642-649.
55. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al.(2007).A randomized, double-blind comparison of olanzapine/ fl uoxetine combination, olanzapine, and fl uoxetine in treatmentresistant major depressive disorder. J Clin Psychiatry, 68:224-236.
56. Trivedi MH, Fava M, Wisniewski SR, Th ase ME, Quitkin F, Warden D, et al. 2006. Medication augmentation aft er the failure of SSRIs for depression. N Engl J Med 354: 1243-1252.
57. Trivedi MH, Lin EH, Katon WJ. 2007. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr; 12 : 1-27.
58. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al; STAR, D Study Team. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR, , , D: implications for clinical practice. Am J Psychiatry 163: 28-40.
59. Vis PM, van Baardewijk M, Einarson TR. 2005. Duloxetine and venlafaxine- XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. A nn . A nn nn Pharmacother 3 9: 1 798-1 807.